Evidence map›Paper›PMID 37768389›Full record

ArticleJournal of neurology2024

Examining the environmental risk factors of progressive-onset and relapsing-onset multiple sclerosis: recruitment challenges, potential bias, and statistical strategies.

Ying Li, Alice Saul, Bruce Taylor, Anne-Louise Ponsonby, Steve Simpson-Yap, Leigh Blizzard, Simon Broadley, Jeannette Lechner-Scott, Ausimmune/AusLong Investigators Group, Rana Karabudak and 47 more

Open access · hybridAbstract read
In one paragraph

Article in Journal of neurology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

57 authors at 20 institutions in 20 countries.

Ying LiMenzies Institute of Medical Research, University of Tasmania, 17 Liverpool Street, Hobart, TAS, 7000, Australia.
Alice SaulMenzies Institute of Medical Research, University of Tasmania, 17 Liverpool Street, Hobart, TAS, 7000, Australia.
Bruce TaylorMenzies Institute of Medical Research, University of Tasmania, 17 Liverpool Street, Hobart, TAS, 7000, Australia.
Anne-Louise PonsonbyFlorey Institute for Neuroscience, University of Melbourne, Melbourne, VIC, Australia.
Steve Simpson-YapMenzies Institute of Medical Research, University of Tasmania, 17 Liverpool Street, Hobart, TAS, 7000, Australia.
Leigh BlizzardMenzies Institute of Medical Research, University of Tasmania, 17 Liverpool Street, Hobart, TAS, 7000, Australia.
Simon BroadleySchool of Medicine and Dentistry, Griffith University, Brisbane, QLD, Australia.
Jeannette Lechner-ScottHunter Medical Research Institute, University of Newcastle, Callaghan, Australia.
Ausimmune/AusLong Investigators Group
Rana KarabudakHacettepe University, Ankara, Turkey.
Francesco PattiDepartment of Medical and Surgical Sciences and Advanced Technologies, GF Ingrassia, Catania, Italy.
Sara EichauHospital Universitario Virgen Macarena, Seville, Spain.
Marco OnofrjUniversity G. d'Annunzio, Chieti, Italy.
Serkan OzakbasDokuz Eylul University, Konak, Izmir, Turkey.
Dana HorakovaCharles University in Prague and General University Hospital, Prague, Czech Republic.
Eva Kubala HavrdovaCharles University in Prague and General University Hospital, Prague, Czech Republic.
Francois Grand'MaisonNeuro Rive-Sud, Quebec, Canada.
Raed AlroughaniAmiri Hospital, Sharq, Kuwait.
Oliver GerlachZuyderland Medical Center, Sittard-Geleen, The Netherlands.
Maria Pia AmatoUniversity of Florence, Florence, Italy.
Ayse AltintasDepartment of Neurology and Koc University Research Center for Translational Medicine (KUTTAM), Koc University, School of Medicine, Istanbul, Turkey.
Marc GirardCHUM and Universite de Montreal, Montreal, Canada.
Pierre DuquetteCHUM and Universite de Montreal, Montreal, Canada.
Yolanda BlancoHospital Clinic de Barcelona, Barcelona, Spain.
Cristina Ramo-TelloHospital Germans Trias i Pujol, Badalona, Spain.
Guy LaureysUniversitary Hospital Ghent, Ghent, Belgium.
Tomas KalincikDepartment of Neurology, Neroimmunology Centre, Royal Melbourne Hospital, Melbourne, Australia.
Samia J KhouryAmerican University of Beirut Medical Center, Beirut, Lebanon.
Vahid ShaygannejadIsfahan University of Medical Sciences, Isfahan, Iran.
Masoud EtemadifarAl Zahra Hospital, Isfahan, Iran.
Bhim SinghalBombay Hospital Institute of Medical Sciences, Mumbai, India.
Saloua MrabetDepartment of Neurology, LR 18SP03, Clinical Investigation Centre Neurosciences and Mental Health, University Hospital Razi-Manouba, Tunis, Tunisia.
Matteo FoschiS. Maria delle Croci Hospital, AUSL Romagna, Ravenna, Italy.
Mario HabekUniversity Hospital Center Zagreb, Zagreb, Croatia.
Nevin JohnMonash Medical Centre, Melbourne, Australia.
Stella HughesRoyal Victoria Hospital, Belfast, UK.
Pamela McCombeRoyal Brisbane and Women's Hospital, Brisbane, Australia.
Radek AmpapaNemocnice Jihlava, Jihlava, Czech Republic.
Anneke van der WaltThe Alfred Hospital, Melbourne, Australia.
Helmut ButzkuevenMonash University, Melbourne, Australia.
Koen de GansGroene Hart Ziekenhuis, Gouda, Netherlands.
Chris McGuiganSt Vincent's University Hospital, Dublin, Ireland.
Celia Oreja-GuevaraHospital Clinico San Carlos, Madrid, Spain.
Maria Jose SaCentro Hospitalar Universitario de Sao Joao, Porto, Portugal.
Thor PetersenAarhus University Hospital, Aarhus, Denmark.
Talal Al-HarbiKing Fahad Specialist Hospital-Dammam, Khobar, Saudi Arabia.
Angel Perez SempereHospital General Universitario de Alicante, Alicante, Spain.
Bart Van WijmeerschPelt and Hasselt University, Hasselt, Belgium.
Nikolaos GrigoriadisAHEPA University Hospital, Thessaloniki, Greece.
Julie PrevostCSSS Saint-Jérôme, Saint-Jerome, Canada.
Orla GraySouth Eastern HSC Trust, Belfast, UK.
Tamara Castillo-TriviñoHospital Universitario Donostia and IIS Biodonostia, San Sebastián, Spain.
Richard MacdonellAustin Health, Melbourne, Australia.
Alessandra LugaresiIRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy.
Seyed Aidin SajediGolestan University of Medical Sciences, Gogan, Iran.
MSBase
Ingrid van der MeiMenzies Institute of Medical Research, University of Tasmania, 17 Liverpool Street, Hobart, TAS, 7000, Australia. ingrid.vandermei@utas.edu.au.
Griffith University · AUUniversity of Tasmania · AUThe University of Melbourne · AUCharles University · CZDokuz Eylül University · TRFernando Pessoa University · PTHospital Clínic de Barcelona · ESIsfahan University of Medical Sciences · IRKoç University · TRMonash University · AUTunis University · TNUniversity College Dublin · IEAHEPA University Hospital · GRAmiri Hospital · KWCegep de Saint Jerome · CAGhent University Hospital · BEHunter Medical Research Institute · AUKing Fahad Specialist Hospital · SAThe University of Queensland · AUUniversity of Chieti-Pescara · IT

Funding

Multiple Sclerosis Australia 14-031
6 · The paper itself

Abstract

It is unknown whether the currently known risk factors of multiple sclerosis reflect the etiology of progressive-onset multiple sclerosis (POMS) as observational studies rarely included analysis by type of onset. We designed a case-control study to examine associations between environmental factors and POMS and compared effect sizes to relapse-onset MS (ROMS), which will offer insights into the etiology of POMS and potentially contribute to prevention and intervention practice. This study utilizes data from the Primary Progressive Multiple Sclerosis (PPMS) Study and the Australian Multi-center Study of Environment and Immune Function (the AusImmune Study). This report outlines the conduct of the PPMS Study, whether the POMS sample is representative, and the planned analysis methods. The study includes 155 POMS, 204 ROMS, and 558 controls. The distributions of the POMS were largely similar to Australian POMS patients in the MSBase Study, with 54.8% female, 85.8% POMS born before 1970, mean age of onset of 41.44 ± 8.38 years old, and 67.1% living between 28.9 and 39.4° S. The POMS were representative of the Australian POMS population. There are some differences between POMS and ROMS/controls (mean age at interview: POMS 55 years vs. controls 40 years; sex: POMS 53% female vs. controls 78% female; location of residence: 14.3% of POMS at a latitude ≤ 28.9°S vs. 32.8% in controls), which will be taken into account in the analysis. We discuss the methodological issues considered in the study design, including prevalence-incidence bias, cohort effects, interview bias and recall bias, and present strategies to account for it. Associations between exposures of interest and POMS/ROMS will be presented in subsequent publications.

Indexed as

Multiple SclerosisMultiple Sclerosis, Chronic ProgressiveAdultAge of OnsetAustraliaCase-Control StudiesFemaleHumansMaleMiddle AgedMulticenter Studies as TopicRecurrenceRisk FactorsBiasCase–controlEnvironmental factorsProgressive-onset multiple sclerosisSubject recruitment

Identifiers

PMID37768389
PMCPMC10770262
OpenAlexW4387116074

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.